JOHN W. KOZARICH - 28 Feb 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role: Director
Signature: By: Charles S. Berkman For: John W. Kozarich
Issuer symbol: LGND
Transactions as of: 28 Feb 2022
Net transactions value: -$1,271
Form type: 4
Filing time: 01 Mar 2022, 15:34:59 UTC
Previous filing: 07 Jun 2021
Next filing: 13 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LGND	Common Stock	Options Exercise	$91,908	+7,335	+21%	$12.53^*	42,117	28 Feb 2022	Direct
transaction	LGND	Common Stock	Sale	$93,179	-908	-2.2%	$102.62	41,209	28 Feb 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LGND	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-7,335	-100%	$0.000000^*	0	28 Feb 2022	Common Stock	7,335	$12.53	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Acquired by a grant of the Board of Directors of the Company at their annual meeting on May 31, 2012, and fully vested on the first anniversary of the grant date.